Assessing the Effect of Including Social Costs in Economic Evaluations of Diabetes-Related Interventions: A Systematic Review.
diabetes
economic evaluation
health technology assessment
informal care
productivity losses
social costs
Journal
ClinicoEconomics and outcomes research : CEOR
ISSN: 1178-6981
Titre abrégé: Clinicoecon Outcomes Res
Pays: New Zealand
ID NLM: 101560564
Informations de publication
Date de publication:
2021
2021
Historique:
received:
12
01
2021
accepted:
09
03
2021
entrez:
6
5
2021
pubmed:
7
5
2021
medline:
7
5
2021
Statut:
epublish
Résumé
The economic burden of diabetes from a societal perspective is well documented in the cost-of-illness literature. However, the effect of considering social costs in the results and conclusions of economic evaluations of diabetes-related interventions remains unknown. To investigate whether the inclusion of social costs (productivity losses and/or informal care) might change the results and conclusions of economic evaluations of diabetes-related interventions. A systematic review was designed and launched on Medline and the Cost-Effectiveness Analysis Registry from the University of Tufts, from the year 2000 until 2018. Included studies had to fulfil the following criteria: i) being an original study published in a scientific journal, ii) being an economic evaluation of an intervention on diabetes, iii) including social costs, iv) being written in English, v) using quality-adjusted life years as outcome, and vi) separating the results according to the perspective applied. From the 691 records identified, 47 studies (6.8%) were selected. Productivity losses were included in 45 of the selected articles (73% used the human capital approach) whereas informal care costs in only 13 (when stated, the opportunity cost method was used in seven studies and the replacement cost in one). The 47 studies resulted in 110 economic evaluation estimations. The inclusion of social costs changed the conclusions in 8 estimations (17%), 6 of them switching from not cost-effective from the healthcare perspective to cost-effective or dominant from the societal perspective. Considering social costs altered the results from cost-effective to dominant in 9 estimations (19%). When social costs are considered, the results and conclusions of economic evaluations performed in diabetes-related interventions can alter. Wide methodological variations have been observed, which limit the comparability of studies and advocate for the inclusion of a wider perspective via the consideration of social costs in economic evaluations and methodological guidelines relating to their estimation and valuation.
Sections du résumé
BACKGROUND
BACKGROUND
The economic burden of diabetes from a societal perspective is well documented in the cost-of-illness literature. However, the effect of considering social costs in the results and conclusions of economic evaluations of diabetes-related interventions remains unknown.
OBJECTIVE
OBJECTIVE
To investigate whether the inclusion of social costs (productivity losses and/or informal care) might change the results and conclusions of economic evaluations of diabetes-related interventions.
METHODS
METHODS
A systematic review was designed and launched on Medline and the Cost-Effectiveness Analysis Registry from the University of Tufts, from the year 2000 until 2018. Included studies had to fulfil the following criteria: i) being an original study published in a scientific journal, ii) being an economic evaluation of an intervention on diabetes, iii) including social costs, iv) being written in English, v) using quality-adjusted life years as outcome, and vi) separating the results according to the perspective applied.
RESULTS
RESULTS
From the 691 records identified, 47 studies (6.8%) were selected. Productivity losses were included in 45 of the selected articles (73% used the human capital approach) whereas informal care costs in only 13 (when stated, the opportunity cost method was used in seven studies and the replacement cost in one). The 47 studies resulted in 110 economic evaluation estimations. The inclusion of social costs changed the conclusions in 8 estimations (17%), 6 of them switching from not cost-effective from the healthcare perspective to cost-effective or dominant from the societal perspective. Considering social costs altered the results from cost-effective to dominant in 9 estimations (19%).
CONCLUSION
CONCLUSIONS
When social costs are considered, the results and conclusions of economic evaluations performed in diabetes-related interventions can alter. Wide methodological variations have been observed, which limit the comparability of studies and advocate for the inclusion of a wider perspective via the consideration of social costs in economic evaluations and methodological guidelines relating to their estimation and valuation.
Identifiants
pubmed: 33953579
doi: 10.2147/CEOR.S301589
pii: 301589
pmc: PMC8092852
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
307-334Informations de copyright
© 2021 Rodriguez-Sanchez et al.
Déclaration de conflit d'intérêts
BRS, IAR, JOM and JLB report to have received funding grants from the European Commission, during the conduct of the study. No other disclosures were reported by any of the authors.
Références
Diabetes Care. 2011 Jun;34(6):1344-9
pubmed: 21562323
Ann Intern Med. 2005 Mar 1;142(5):323-32
pubmed: 15738451
Diabet Med. 2015 May;32(5):618-26
pubmed: 25483869
Qual Health Res. 2013 Nov;23(11):1506-20
pubmed: 24096518
World J Psychiatry. 2016 Mar 22;6(1):7-17
pubmed: 27014594
Value Health. 2021 Mar;24(3):431-442
pubmed: 33641778
J Pain. 2017 Apr;18(4):405-414
pubmed: 27965045
PLoS One. 2016 Dec 9;11(12):e0167759
pubmed: 27936083
Diabetes Care. 2017 Jan;40(Suppl 1):S11-S24
pubmed: 27979889
Value Health. 2015 Mar;18(2):271-7
pubmed: 25773562
Ann Intern Med. 2005 Aug 16;143(4):251-64
pubmed: 16103469
Ann Intern Med. 2005 Jul 19;143(2):89-99
pubmed: 16027450
Eur Heart J. 2000 May;21(9):733-9
pubmed: 10739728
BMJ Open. 2020 May 5;10(5):e033231
pubmed: 32376746
J Med Econ. 2016;19(2):121-34
pubmed: 26413789
Value Health. 2012 Jul-Aug;15(5):632-8
pubmed: 22867771
PLoS One. 2013 Nov 14;8(11):e80672
pubmed: 24244703
Diabetes Res Clin Pract. 2017 Jun;128:6-14
pubmed: 28432898
J Med Econ. 2016 Jul;19(7):663-71
pubmed: 26882365
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
Cost Eff Resour Alloc. 2014 Jul 28;12:17
pubmed: 25089122
Eur J Health Econ. 2018 Mar;19(2):189-201
pubmed: 28190188
Curr Med Res Opin. 2008 May;24(5):1417-28
pubmed: 18400145
Qual Life Res. 2017 Jun;26(6):1379-1386
pubmed: 27995368
Diabet Med. 2018 Feb;35(2):214-222
pubmed: 29150861
Lancet. 2016 Oct 8;388(10053):1603-1658
pubmed: 27733283
Diabetes Care. 2003 Sep;26(9):2518-23
pubmed: 12941712
Int J Behav Nutr Phys Act. 2018 Mar 14;15(1):23
pubmed: 29540227
PLoS One. 2014 Sep 09;9(9):e107225
pubmed: 25203633
Diabetes Care. 2014 Sep;37(9):2557-64
pubmed: 25147254
J Med Econ. 2014 Sep;17(9):658-69
pubmed: 24950434
Value Health. 2005 Jan-Feb;8(1):3-9
pubmed: 15841889
Diabetes Res Clin Pract. 2016 Jul;117:48-54
pubmed: 27329022
Health Aff (Millwood). 2014 Jan;33(1):110-5
pubmed: 24395942
Diabet Med. 2012 Jul;29(7):855-62
pubmed: 22537247
Health Technol Assess. 2010 May;14(22):1-101, iii-iv
pubmed: 20483060
Diabetes Ther. 2017 Oct;8(5):1015-1030
pubmed: 28871565
Med Care. 2002 May;40(5):387-94
pubmed: 11961473
Diabetes Care. 2011 Mar;34(3):622-7
pubmed: 21273495
Ophthalmology. 2016 Dec;123(12):2571-2580
pubmed: 27726962
Diabet Med. 2017 Aug;34(8):1136-1144
pubmed: 28294392
J Med Econ. 2016;19(3):236-42
pubmed: 26510389
Diabetes Res Clin Pract. 2017 May;127:59-69
pubmed: 28319803
Am J Manag Care. 2013 May;19(5):421-30
pubmed: 23781894
Scand J Public Health. 2011 Feb;39(1):79-87
pubmed: 20688795
Eur J Health Econ. 2017 Nov;18(8):937-965
pubmed: 27752788
J Med Econ. 2009 Jun;12(2):114-23
pubmed: 19545216
Diabetes Ther. 2014 Dec;5(2):591-607
pubmed: 25213800
J Med Econ. 2013 Dec;16(12):1442-52
pubmed: 24147661
BMC Health Serv Res. 2014 Nov 21;14:579
pubmed: 25413154
Diabetes Care. 2018 May;41(5):963-970
pubmed: 29475843
Diabetes Res Clin Pract. 2018 Apr;138:271-281
pubmed: 29496507
PLoS Med. 2010 Feb 23;7(2):e1000236
pubmed: 20186272
Curr Med Res Opin. 2017 Apr;33(4):647-655
pubmed: 28035840
J Med Econ. 2012;15(5):977-86
pubmed: 22563742
Clin Ther. 2011 Nov;33(11):1698-712
pubmed: 22018679
Adv Ther. 2008 Apr;25(4):285-99
pubmed: 18414816
Eur J Health Econ. 2019 Nov;20(8):1207-1236
pubmed: 31342208
Diabet Med. 2009 Sep;26(9):928-34
pubmed: 19719715
Int J Technol Assess Health Care. 2007 Spring;23(2):177-83
pubmed: 17493303
Pharmacoeconomics. 2015 Feb;33(2):123-35
pubmed: 25315368
PLoS One. 2018 Feb 6;13(2):e0191953
pubmed: 29408938
Health Econ Rev. 2020 Sep 22;10(1):32
pubmed: 32964372
Diabetes Technol Ther. 2016 Feb;18(2):75-84
pubmed: 26646072
J Acad Nutr Diet. 2012 Nov;112(11):1747-54
pubmed: 23102174
Eur J Health Econ. 2016 May;17(4):391-402
pubmed: 25876834
Diabetes Care. 2010 Jun;33(6):1269-74
pubmed: 20332354
Wien Med Wochenschr. 2006 Dec;156(23-24):628-32
pubmed: 17211768
Pharmacoeconomics. 2017 Feb;35(2):141-162
pubmed: 27752998
Prim Care Diabetes. 2012 Dec;6(4):303-12
pubmed: 22595032
Eur J Health Econ. 2010 Oct;11(5):513-20
pubmed: 20405159
BMC Pregnancy Childbirth. 2012 Jul 04;12:64
pubmed: 22762376
J Med Econ. 2011;14(3):357-66
pubmed: 21563878
BMC Health Serv Res. 2006 Jun 06;6:67
pubmed: 16756662
Value Health. 2012 Sep-Oct;15(6):975-81
pubmed: 22999150
J Med Econ. 2015;18(8):573-85
pubmed: 25853868
BMC Endocr Disord. 2016 Jun 09;16(1):35
pubmed: 27278922
Curr Med Res Opin. 2010 Aug;26(8):1827-34
pubmed: 20491613
Global Health. 2013 May 01;9:17
pubmed: 23635075
Adv Ther. 2006 Mar-Apr;23(2):191-207
pubmed: 16751153
J Public Health (Oxf). 2016 Dec 02;38(4):782-792
pubmed: 28158645
J Diabetes Sci Technol. 2011 May 01;5(3):501-13
pubmed: 21722566
Diabetes Care. 2018 May;41(5):917-928
pubmed: 29567642
Acta Psychiatr Scand. 2011 Sep;124(3):214-25
pubmed: 21609324
J Med Econ. 2016 Aug;19(8):742-9
pubmed: 26985982
Int J Technol Assess Health Care. 2017 Jan;33(2):251-260
pubmed: 28641592
Qual Life Res. 2004 Aug;13(6):1081-8
pubmed: 15287274
Endocrinol Nutr. 2013 Oct;60(8):447-55
pubmed: 23726468
Am J Manag Care. 2015 Jan;21(4 Suppl):S63-72
pubmed: 25734663
Lancet Diabetes Endocrinol. 2020 Oct;8(10):855-867
pubmed: 32946822
Diabet Med. 2011 Apr;28(4):470-9
pubmed: 21392068
Ophthalmology. 2015 Jul;122(7):1416-25
pubmed: 25935787